Press Releases

Apr 23, 2018

Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada® (alemtuzumab) in Clinical Trials

* At seven years in the extension of two Phase III pivotal studies, 59 and 47 percent of patients received no additional treatment after the initial two courses of Lemtrada
Apr 23, 2018

Relapsing MS Patients Who Switched to Aubagio® (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
Apr 5, 2018

New Sanofi insulin savings program aims to lower out-of-pocket costs for people living with diabetes

- The new Insulins VALyou Savings Program improves affordability for eligible people prescribed Lantus® (insulin glargine 100 Units/mL) and Admelog® (insulin lispro injection)
Mar 27, 2018

FDA approves Toujeo® Max SoloStar®

* Max SoloStar holds more insulin than any other long-acting insulin pen
- Photos 1
Mar 27, 2018

New survey reveals many misconceptions exist about allergies, illustrating the need for greater education

- Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts
- Video 4
- Photos 3

Show per page